Ultrasound plus GCase treatment for Parkinson’s symptoms
Part of Brain & nervous system clinical trials.
This trial studies whether MR-guided focused ultrasound combined with an enzyme treatment called GCase can improve Parkinson’s disease. It includes people with specific Parkinson’s diagnosis and scan findings, and it may help those with certain genetic or imaging markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 35 and 80 years old and can give informed consent.
- You’ve had Parkinson’s disease for at least 2 years and are on stable Parkinson’s medicines for 90 days or more.
- Your Parkinson’s symptoms are mild to moderate (Hoehn and Yahr Stage 1–3) while you’re taking Parkinson’s medication.
- Your brain scan shows a dopamine deficit (a DAT SPECT scan result must be positive).
- If you join the GBA study group, you must have at least one GBA gene mutation; if not, you must have two normal (wild-type) GBA copies.
- You must be able to safely have MRI and ultrasound with contrast, and you should not have certain heart, kidney, infection, stroke/TIA, or prior brain surgery issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called DSP-1083 for people with Parkinson's disease whose symptoms are not well controlled with standard medications. The study will check if it is safe and if it helps improve movement and daily function.
This study tests a non-invasive ultrasound treatment that gently stimulates a small part of the brain to see if it can improve Parkinson's symptoms like movement and stiffness. It may be an option for people who have not had brain surgery yet.
This trial tests a noninvasive ultrasound treatment targeting a brain area called the pedunculopontine nucleus to help reduce freezing of gait (a sudden inability to walk) in Parkinson's disease. If you have Parkinson's and experience freezing, you may be eligible to try this new approach.
This trial tests whether a non-invasive ultrasound treatment, called transcranial focused ultrasound stimulation (tFUS), can improve movement and thinking in people with Parkinson's disease. It may be an option for those whose symptoms are not well controlled by medication alone.
This trial tests a non-invasive treatment using focused ultrasound to target a small area in the brain that helps control movement. It aims to reduce Parkinson's symptoms like tremors, stiffness, and involuntary movements, and is for people who have had Parkinson's for a while and are already taking medication.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.